Impact of Neoadjuvant Endocrine Therapy on Tumor Transcriptome in Patients With Early-Stage Breast Cancer From the FLEX Trial
PUBLICATION: San Antonio Breast Cancer Symposium 2022 TITLE: Impact Read More
FOCUS Trial: Validation of MammaPrint for ≥ 70yrs w/ UltraLow risk of distant recurrence
J Geriatr Oncol. 2022 Nov;13(8):1172-1177 Authors: Noordhoek et al.
Read MoreSTO-5 Trial: 20-yr benefit from Adjuvant Goserelin & Tamoxifen, JCO 2022
Journal of Clinical Oncology, 40:4071-4082 Authors: Johansson et al.
Read MoreI-SPY2: ImPrint immune signature identifies ESBC patients who benefit from PD1 checkpoint inhibition
ASCO 2022, Poster #514 Authors: Kuilman et al.
Read MoreIKA Trial: MammaPrint UltraLow & Limited Systemic Endocrine Overtreatment
IKA Trial, Breast Cancer Res Treat, 2022; 194(2): 265-278 Authors: Opdam, et al.
Read MoreBudget impact analysis for the Health Care Package by using MammaPrint in Belgium
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors De Lameillieure Read More
Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors Esther Schuler(1), Read More
MINDACT: Outcomes of any adjuvant systemic treatment in ESBC
Annals of Oncology, Volume 33, Issue 3, March 2022, Pages 310-320 Authors: Lopes Cardozo et al.
Read MoreMINDACT Trial: Outcome of Patients with UltraLow Risk, JCO 2022
Journal of Clinical Oncology, Volume 40, Number 12, January 21, 2022 Authors: Audeh et al.
Read MoreDurvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read More
